



(REVIEW ARTICLE)



Parsonage-Turner Syndrome: An update

Amália Cinthia Meneses do Rêgo ¹ and Irami Araújo-Filho ^{1, 2, *}

¹ *Institute of Teaching, Research, and Innovation, Liga Contra o Câncer – Natal – Brazil.*

² *Postgraduate Program in Biotechnology at Potiguar University, Potiguar University (UnP) – Natal/RN - Brazil.*

World Journal of Advanced Research and Reviews, 2024, 23(01), 2882–2889

Publication history: Received on 17 June 2024; revised on 28 July 2024; accepted on 30 July 2024

Article DOI: <https://doi.org/10.30574/wjarr.2024.23.1.2253>

Abstract

Parsonage-Turner Syndrome (PTS), known as Neuralgic Amyotrophy or Brachial Plexus Neuritis, is a rare neurological disorder characterized by sudden onset shoulder pain followed by muscle weakness and atrophy. Despite advancements in medical research, the absence of standardized diagnostic and treatment protocols poses significant challenges. This review explores the multifaceted aspects of PTS, including its genetic predispositions, diagnostic advancements, treatment efficacy, and the long-term impacts on patients' quality of life. The heterogeneity of PTS presentations, the lack of specific biomarkers, and the unclear etiology contribute to the complexities in managing this condition. While current treatments vary from conservative to aggressive interventions, their efficacy remains inconsistent due to the syndrome's unpredictable prognosis. The disease's social and psychological impacts necessitate a comprehensive, multidisciplinary approach to patient care. This review underscores the need for further research to elucidate PTS's genetic and immunological underpinnings, develop more accurate diagnostic tools, and establish evidence-based treatment guidelines.

Keywords: Brachial Plexus Neuritis; Parsonage-Turner Syndrome; Neuralgic Amyotrophy; Physiopathology; Diagnosis; Therapy.

1. Introduction

Parsonage-Turner Syndrome (PTS), or neuralgic amyotrophy or brachial plexus neuritis, is a rare peripheral nerve disorder characterized by sudden, severe shoulder and upper arm pain followed by marked muscle weakness or atrophy¹.

This syndrome has been a subject of medical scrutiny due to its abrupt onset and the significant impact it can have on the quality of life. Despite its identification in the mid-20th century, the pathogenesis, optimal diagnostic strategies, and treatment protocols for PTS remain under continuous exploration and debate^{2,3}.

The incidence of PTS is reported to be about 1-3 cases per 100,000 people annually, affecting men more frequently than women and showing no clear preference for any specific age group⁴.

However, a bimodal age distribution has been noted, with peaks in young adults and individuals in their mid-fifties. The syndrome affects all races and ethnicities⁵.

PTS presents acutely with pain around the shoulder girdle, radiating toward the arm and hand. This pain, often described as sharp or throbbing, is usually severe enough to wake the patient from sleep and may last for several days to weeks before subsiding gradually⁶. Following the resolution of pain, patients experience varying degrees of motor weakness, muscular atrophy, or sensory disturbances, primarily affecting the proximal arm muscles⁷.

* Corresponding author: Irami Araújo-Filho

The exact pathophysiological mechanisms underlying PTS are still not fully understood. It is hypothesized to involve an immune-mediated inflammatory response that leads to damage within the brachial plexus⁸.

Some researchers propose that the syndrome may be triggered by viral infections, surgical procedures, vaccinations, or strenuous physical activity, which somehow precipitate an autoimmune response against peripheral nerve fibers⁹.

Recent studies have explored the potential genetic predisposition to PTS, suggesting that certain hereditary traits may increase susceptibility to the syndrome¹⁰. Familial cases of PTS have been documented, indicating a possible genetic component that could predispose individuals to nerve inflammation and damage¹¹.

Diagnosing PTS can be challenging due to its sudden onset and the variety of its symptoms, which can mimic other neurological conditions. Diagnosis is primarily clinical, supported by the patient's history and physical examination findings¹².

Electromyography (EMG) and nerve conduction studies can help assess the extent of nerve involvement and exclude other differential diagnoses. Recent advances in imaging, particularly MRI and ultrasound, have improved the ability to visualize inflammatory changes in the brachial plexus and exclude other structural causes of the symptoms¹³⁻¹⁵.

The management of PTS is primarily supportive and symptomatic. Initial treatment typically involves pain management with NSAIDs, corticosteroids, or opioid analgesics¹⁶. Once the acute pain subsides, physical therapy is crucial to prevent muscle atrophy and maintain range of motion. In some severe cases, surgical intervention may be considered¹⁷.

The prognosis of PTS varies widely. While many patients experience significant spontaneous recovery, especially in muscle strength, within the first two years, a substantial proportion may have residual weakness, sensory abnormalities, or pain. Early intervention and rehabilitation are crucial to improving outcomes^{18,19}.

Raising awareness about PTS among healthcare providers is critical for early diagnosis and management. Educating patients who undergo surgeries involving the shoulder or those engaging in activities that could trigger PTS is also vital for prevention and early treatment²⁰.

Ongoing research is essential to unraveling the complex pathophysiology of PTS and developing more effective treatments. Current studies focus on the molecular and immunological aspects of the syndrome, aiming to identify specific biomarkers for early diagnosis and targeted therapy^{21,22}.

The objective of this review article on Parsonage-Turner Syndrome is to provide a comprehensive update on the multiple facets of the condition, encompassing its epidemiology, clinical presentation, pathophysiology, diagnostic approaches, and management strategies⁴.

The review aims to elucidate the syndrome's pathogenic mechanisms, examining current theories regarding its immunological and genetic causes. It also seeks to clarify the relationship between the clinical manifestations and the anatomical features observed in affected individuals⁸.

However, the article intends to summarize and evaluate the latest diagnostic modalities that enhance the accuracy of detecting this condition. Management strategies will be thoroughly reviewed, emphasizing evidence-based treatments, and integrating multidisciplinary approaches to optimize patient outcomes¹⁰.

This study also plans to highlight gaps in the current knowledge and suggest directions for future research, ensuring that the medical community remains abreast of the latest advancements and understands the complex nature of Parsonage-Turner Syndrome¹⁶.

This comprehensive synthesis of current evidence and new insights aims to assist healthcare professionals in refining their diagnostic and therapeutic approaches to this challenging and often underrecognized condition.

2. Methods

The research methodology for this review was designed to investigate Parsonage-Turner Syndrome (PTS), focusing on its physiopathology, diagnosis, and therapy. Multiple reputable databases were utilized to ensure comprehensive coverage of relevant scientific and medical literature, including PubMed, Scopus, SciELO, Embase, and Web of Science,

which were recognized for their extensive collections of peer-reviewed publications. Google Scholar was employed to access gray literature, which often includes significant studies not available in standard academic journals. The primary objective was to understand the current knowledge regarding the incidence, underlying mechanisms, and treatment options for PTS. To achieve this, search parameters were carefully crafted using relevant keywords such as "brachial plexus neuritis," "Parsonage-Turner syndrome," "neuralgic amyotrophy," "physiopathology," "diagnosis," and "therapy." This strategic combination of search terms ensured the retrieval of studies directly pertinent to the research objectives. Inclusion criteria encompassed a broad spectrum of study designs, including randomized controlled trials, cohort studies, case-control studies, systematic reviews, and meta-analyses. This approach aimed to capture diverse evidence and perspectives on PTS. Exclusion criteria were established to filter out studies focusing on unrelated pathologies, non-PTS-related nerve conditions, or other age groups. Two independent reviewers initially screened each study's title and abstract for relevance and compliance with predefined criteria to ensure methodological rigor. Any discrepancies between the reviewers were resolved through consultation with a third reviewer, thereby minimizing bias and ensuring consistent selection. This dual-review process ensured that the final dataset comprised studies meeting the highest standards of relevance and quality. This systematic approach to the literature review provided a solid foundation for evaluating and synthesizing the findings. It ensured that this study's conclusions were based on a comprehensive and critically assessed body of scientific evidence regarding Parsonage-Turner Syndrome, including its genetic factors, diagnostic advancements, treatment protocols, and impact on the patient's quality of life.

3. Results and Discussion

The discussion surrounding Parsonage-Turner Syndrome (PTS) reflects a deepening understanding of this complex condition, yet significant gaps persist in areas ranging from genetic predisposition to effective treatment protocols²³.

Despite its clear clinical presentation, the specific genetic factors predisposing individuals to PTS remain elusive. While familial cases suggest a genetic component, the exact genes and their interactions have not been fully delineated⁴⁵. Current hypotheses propose a multifactorial origin involving genetic susceptibilities, such as variations in immune response genes, and environmental triggers like viral infections or immunizations²⁴⁻²⁶.

Advanced genomic studies, including genome-wide association studies, could provide insights into the genetic architecture of PTS, potentially identifying risk alleles and gene-environment interactions that contribute to the syndrome²⁷.

Genetic researchers continue to explore the possibility of a polygenic nature or significant gene-environment interactions influencing PTS. Genomic technologies, such as whole-exome sequencing or genome-wide association studies, hold promise in identifying genetic variants predisposing individuals to PTS, which could lead to predictive genetic testing and more precise familial counseling²⁸⁻³⁰.

Innovations in imaging technology play a pivotal role in diagnosing PTS. High-resolution magnetic resonance imaging (MRI) and ultrasound have substantially improved our ability to visualize nerve damage³¹. The advent of magnetic resonance neurography (MRN) has further enhanced this capability by providing detailed images of peripheral nerve structures, potentially allowing for earlier and more accurate diagnoses. Future advancements may include the integration of artificial intelligence to interpret these complex images, offering even greater diagnostic precision³²⁻³⁴.

Biomarkers have immense potential to transform PTS's diagnostic and therapeutic landscape, aims to identify specific biomarkers for early diagnosis and targeted therapy²⁸. A comprehensive biomarker panel, including inflammatory markers and particular antibodies, could facilitate rapid, noninvasive diagnosis and monitor therapeutic responses, enabling timely interventions that improve outcomes^{35,36}.

Due to its unpredictable prognosis, treatment protocols for PTS vary, ranging from conservative approaches like physical therapy to aggressive interventions such as corticosteroids and immunoglobulin therapy³⁷.

The efficacy of these treatments remains variable, highlighting the need for standardized, evidence-based guidelines. However, exploring tailored immunomodulatory treatments and biological agents targeting specific inflammatory pathways may provide more effective treatment options³⁸.

The effectiveness of treatments for PTS varies, reflecting the syndrome's unpredictable nature and diverse manifestations. Current management strategies are primarily empirical, with corticosteroids and intravenous immunoglobulins (IVIG) frequently used despite limited high-quality evidence for their efficacy³⁹⁻⁴¹.

Physical therapy is a cornerstone of treatment, focusing on maintaining muscle function and range of motion. The optimal treatment protocols for PTS are yet to be established through rigorous, controlled clinical trials³⁶. Developing evidence-based guidelines will require a coordinated effort to study the long-term outcomes of various therapeutic approaches and their impact on disease progression^{42,43}.

The absence of a standardized treatment and diagnostic protocol for Parsonage-Turner Syndrome (PTS) is attributed to several complex factors. One of the primary challenges in standardizing treatment lies in the heterogeneity of PTS presentations^{7,19}. The disease's symptoms, severity, and progression vary significantly among individuals, complicating the development of a universally applicable treatment regimen. This variability makes it difficult to establish uniform treatment protocols and challenges the efficacy of potential therapies across different patient groups⁴⁴.

The diagnosis of PTS suffers from limitations due to the lack of specific biomarkers and the reliance on clinical symptoms and imaging findings for confirmation³¹⁻³³. The syndrome often presents with symptoms that mimic other neurological disorders, leading to potential misdiagnosis or delayed diagnosis. The diagnostic process is further complicated by the transient nature of some symptoms, which may resolve before the patient seeks medical advice⁴⁵.

Another significant hurdle is the unclear etiology of PTS. While genetic predispositions and autoimmune responses are suspected, the exact triggers and pathophysiological mechanisms remain poorly understood³⁴. This gap in understanding the fundamental causes of PTS hampers the development of targeted diagnostics and treatments¹⁵.

The rarity of PTS contributes to the difficulty in researching and understanding the syndrome more comprehensively. Limited patient numbers make conducting large-scale, statistically robust studies necessary for developing evidence-based guidelines challenging⁴⁶.

This scarcity of clinical solid data restricts the ability to test and validate new diagnostic methods and treatments, which are crucial for establishing standard protocols^{38,47}.

The development of standardized diagnostic and treatment protocols for Parsonage-Turner Syndrome is impeded by the disease's variable clinical manifestations, the absence of specific diagnostic markers, unclear etiology, and the challenges posed by its rarity. These factors collectively hinder the advancement of universally accepted medical practices for managing PTS⁴⁸.

The link between PTS and various systemic health conditions, such as viral infections and autoimmune disorders, suggests a complex interplay that contributes to the syndrome's pathogenesis. These relationships could uncover new therapeutic targets and enhance our overall approach to treatment^{10,49}.

Long-term effects of PTS, including persistent pain, muscle atrophy, and sensory deficits, necessitate a multidisciplinary approach to management². This should include advanced physical therapy techniques, neuromuscular electrical stimulation, and potentially regenerative medicine approaches like stem cell therapy, aiming at functional recovery and improving quality of life⁵⁰.

Social and psychological impacts of PTS are profound. Patients often face significant challenges in daily activities and employment, which can lead to social isolation and psychological distress⁹⁻¹¹. Comprehensive management strategies should, therefore, also incorporate psychological support and social services to improve patients' overall well-being and societal integration⁵¹.

The potential long-term impacts of PTS on patients' quality of life are significant and can include persistent pain, sensory disturbances, and functional disability due to muscle atrophy and weakness³⁴. These sequelae can profoundly affect personal and professional aspects of life, leading to psychological distress and socioeconomic challenges²⁶.

A comprehensive multidisciplinary approach is essential for addressing these impacts. To provide holistic care, this approach should integrate medical treatments with physical and occupational therapies, pain management, psychological support, and social services⁵².

Various specialists such as neurologists, physiotherapists, occupational therapists, pain specialists, and psychologists, this strategy aims to enhance recovery, improve functional outcomes, and support patients in adapting to lifestyle changes imposed by the syndrome^{53,54}.

Considering the current treatment landscape, there is an ongoing debate about the optimal approach for active PTS, with choices often tailored to individual patient circumstances⁴⁴. Research into the comparative effectiveness of different treatment modalities, especially the roles of immunotherapy versus corticosteroids, is crucial to optimizing patient care⁵⁵.

Looking to the future, the research community remains hopeful about developing specific, targeted therapies based on a deeper understanding of PTPTS's underlying mechanisms³⁷. Clinical trials and studies are expected to play a critical role in this endeavor, potentially leading to breakthroughs that could offer long-term relief and improve the lives of those affected by this debilitating condition^{8,29}.

While our understanding of Parsonage-Turner Syndrome has advanced, significant research efforts are still required to fill the existing knowledge gaps⁴⁸. Future studies should focus on genetic factors, advanced diagnostic tools, effective biomarkers, and comprehensive, evidence-based treatment protocols. These areas will enhance our understanding and significantly improve the quality of life for those affected by PTS^{51,56}.

4. Conclusion

In conclusion, Parsonage-Turner Syndrome (PTS) remains poorly understood, with significant gaps in its genetic basis, diagnostic methods, and treatment protocols. Advances in genetic research, imaging, and biomarkers are promising but incomplete.

The variability in treatment efficacy underscores the need for standardized, evidence-based approaches. Future research should focus on identifying genetic markers, improving diagnostics, and developing targeted therapies to enhance patient outcomes. A multidisciplinary approach is crucial for comprehensive management of PTS, addressing its multifaceted impacts on patients' lives.

Compliance with ethical standards

Acknowledgments

The authors thank the Federal University of Rio Grande do Norte, Potiguar University, and Liga Contra o Cancer for supporting this study.

Disclosure of conflict of interest

The authors declare that there is no conflict of interest.

References

- [1] Gstoettner C, Mayer JA, Rassam S, Hruby LA, Salminger S, Sturma A, Aman M, Harhaus L, Platzgummer H, Aszmann OC. Neuralgic amyotrophy: a paradigm shift in diagnosis and treatment. *J Neurol Neurosurg Psychiatry*. 2020 Aug;91(8):879-888. doi: 10.1136/jnnp-2020-323164.
- [2] Gilcrease-Garcia BM, Deshmukh SD, Parsons MS. Anatomy, Imaging, and Pathologic Conditions of the Brachial Plexus. *Radiographics*. 2020 Oct;40(6):1686-1714. doi: 10.1148/rg.2020200012.
- [3] Finsterer J. Neurological Adverse Reactions to SARS-CoV-2 Vaccines. *Clin Psychopharmacol Neurosci*. 2023 May 30;21(2):222-239. doi: 10.9758/cpn.2023.21.2.222.
- [4] Van Eijk JJ, Groothuis JT, Van Alfen N. Neuralgic amyotrophy: An update on diagnosis, pathophysiology, and treatment. *Muscle Nerve*. 2016 Mar;53(3):337-50. doi: 10.1002/mus.25008.
- [5] Meiling JB, Boon AJ, Niu Z, Howe BM, Hoskote SS, Spinner RJ, Klein CJ. Parsonage-Turner Syndrome and Hereditary Brachial Plexus Neuropathy. *Mayo Clin Proc*. 2024 Jan;99(1):124-140. doi: 10.1016/j.mayocp.2023.06.011.
- [6] Naum R, Gwathmey KG. Autoimmune polyneuropathies. *Handb Clin Neurol*. 2023;195:587-608. doi: 10.1016/B978-0-323-98818-6.00004-2.
- [7] Ijspeert J, Janssen RMJ, van Alfen N. Neuralgic amyotrophy. *Curr Opin Neurol*. 2021 Oct 1;34(5):605-612. doi: 10.1097/WCO.0000000000000968.

- [8] Rothrock RJ, Elarjani T, Levi AD. Neurosurgical Mimics. *Neurol Clin.* 2022 May;40(2):455-469. doi: 10.1016/j.ncl.2021.11.013.
- [9] Expert Panel on Neurologic Imaging;; Bykowski J, Aulino JM, Berger KL, Cassidy RC, Choudhri AF, Kendi AT, Kirsch CFE, Luttrull MD, Sharma A, Shetty VS, Than K, Winfree CJ, Cornelius RS. ACR Appropriateness Criteria Plexopathy. *J Am Coll Radiol.* 2017 May;14(5S):S225-S233. doi: 10.1016/j.jacr.2017.02.002.
- [10] Stecco A, Pirri C, Stecco C. Fascial entrapment neuropathy. *Clin Anat.* 2019 Oct;32(7):883-890. doi: 10.1002/ca.23388.
- [11] Seror P. Neuralgic amyotrophy. An update. *Joint Bone Spine.* 2017 Mar;84(2):153-158. doi: 10.1016/j.jbspin.2016.03.005.
- [12] Tjoumakaris FP, Anakwenze OA, Kancherla V, Pulos N. Neuralgic amyotrophy (Parsonage-Turner syndrome). *J Am Acad Orthop Surg.* 2012 Jul;20(7):443-9. doi: 10.5435/JAAOS-20-07-443.
- [13] Mastroianni A, Mauro MV. Parsonage-Turner syndrome and cytomegalovirus disease. *Clin Neuropathol.* 2022 May-Jun;41(3):135-144. doi: 10.5414/NP301409.
- [14] Smith CC, Bevelaqua AC. Challenging pain syndromes: Parsonage-Turner syndrome. *Phys Med Rehabil Clin N Am.* 2014 May;25(2):265-77. doi: 10.1016/j.pmr.2014.01.001.
- [15] Ameer MZ, Haiy AU, Bajwa MH, Abeer H, Mustafa B, Ameer F, Amjad Z, Rehman AU. Association of Parsonage-Turner syndrome with COVID-19 infection and vaccination: a systematic review. *J Int Med Res.* 2023 Jul;51(7):3000605231187939. doi: 10.1177/03000605231187939.
- [16] Cornea A, Lata I, Simu M, Rosca EC. Parsonage-Turner Syndrome Following SARS-CoV-2 Infection: A Systematic Review. *Biomedicines.* 2023 Mar 9;11(3):837. doi: 10.3390/biomedicines11030837.
- [17] Sumner AJ. Idiopathic brachial neuritis. *Neurosurgery.* 2009 Oct;65(4 Suppl):A150-2. doi: 10.1227/01.NEU.0000345355.59438.D1.
- [18] Kerwin SC, Taylor AR. Neurologic Causes of Thoracic Limb Lameness. *Vet Clin North Am Small Anim Pract.* 2021 Mar;51(2):357-364. doi: 10.1016/j.cvsm.2020.12.003.
- [19] Dedaev SI, Druzhinina ES, Druzhinin DS, Tumurov DA, Ilyasov SV. Nevralgicheskaya amiotrofiya [Neuralgic amyotrophy]. *Zh Nevrol Psikhiatr Im S S Korsakova.* 2022;122(1):8-14. doi: 10.17116/jnevro20221220118.
- [20] Farr E, D'Andrea D, Franz CK. Phrenic Nerve Involvement in Neuralgic Amyotrophy (Parsonage-Turner Syndrome). *Sleep Med Clin.* 2020 Dec;15(4):539-543. doi: 10.1016/j.jsmc.2020.08.002.
- [21] Stutz CM. Neuralgic amyotrophy: Parsonage-Turner Syndrome. *J Hand Surg Am.* 2010 Dec;35(12):2104-6. doi: 10.1016/j.jhssa.2010.09.010.
- [22] Cignetti NE, Cox RS, Baute V, McGhee MB, van Alfen N, Strakowski JA, Boon AJ, Norbury JW, Cartwright MS. A standardized ultrasound approach in neuralgic amyotrophy. *Muscle Nerve.* 2023 Jan;67(1):3-11. doi: 10.1002/mus.27705.
- [23] Rosca EC, Al-Qiami A, Cornea A, Simu M. Parsonage-Turner Syndrome following COVID-19 Vaccination: A Systematic Review. *Vaccines (Basel).* 2024 Mar 14;12(3):306. doi: 10.3390/vaccines12030306.
- [24] Rotondo E, Pellegrino N, Di Battista C, Graziosi A, Di Stefano V, Striano P. Clinico-diagnostic features of neuralgic amyotrophy in childhood. *Neurol Sci.* 2020 Jul;41(7):1735-1740. doi: 10.1007/s10072-020-04314-8.
- [25] Firmino GF, Schulze ML, Schlindwein MAM, Rampeloti B, Gonçalves MVM, Maçaneiro CH, Dos Santos RA. Neuralgic Amyotrophy: Its Importance in Orthopedics Practice. *Spine Surg Relat Res.* 2021 Apr 28;5(4):232-237. doi: 10.22603/ssrr.2021-0014.
- [26] Joaquim AF, Makhni MC, Riew KD. Post-operative nerve injuries after cervical spine surgery. *Int Orthop.* 2019 Apr;43(4):791-795. doi: 10.1007/s00264-018-4257-4.
- [27] Mortazavi SMJ, Razzaghof M, Ghasemi MA. Parsonage-Turner Syndrome and Closed-Incision Negative-Pressure Wound Therapy After Total Hip Arthroplasty in a Case of Marfan Syndrome. *Arthroplast Today.* 2022 Jan 20;14:1-5. doi: 10.1016/j.artd.2021.10.006.
- [28] Xiao R, Chen J, Zeng C, Feng X, Li T, Das SK, Li B, Zhang C, Yang H. Development of magnetic resonance imaging of brachial plexus neuralgia. *Neurol Sci.* 2022 Mar;43(3):1685-1693. doi: 10.1007/s10072-022-05915-1.

- [29] Cintas P. Benign focal amyotrophy. *Rev Neurol (Paris)*. 2017 May;173(5):338-344. doi: 10.1016/j.neurol.2017.03.016.
- [30] Blum A, Lecocq S, Louis M, Wassel J, Moisei A, Teixeira P. The nerves around the shoulder. *Eur J Radiol*. 2013 Jan;82(1):2-16. doi: 10.1016/j.ejrad.2011.04.033.
- [31] Sureka J, Cherian RA, Alexander M, Thomas BP. MRI of brachial plexopathies. *Clin Radiol*. 2009 Feb;64(2):208-18. doi: 10.1016/j.crad.2008.08.011.
- [32] McCarty EC, Tsairis P, Warren RF. Brachial neuritis. *Clin Orthop Relat Res*. 1999 Nov;(368):37-43.
- [33] Meuleman J, Timmerman V, Van Broeckhoven C, De Jonghe P. Hereditary neuralgic amyotrophy. *Neurogenetics*. 2001 Jul;3(3):115-8. doi: 10.1007/s100480100109.
- [34] Chance PF, Windebank AJ. Hereditary neuralgic amyotrophy. *Curr Opin Neurol*. 1996 Oct;9(5):343-7. doi: 10.1097/00019052-199610000-00005.
- [35] Mendoza-Lopez C, Lopez-Lopez P, Atienza-Ayala S, Rivero-Juarez A, Benito R. Parsonage-Turner syndrome associated with hepatitis E infection in immunocompetent patients. *Virus Res*. 2020 Dec;290:198165. doi: 10.1016/j.virusres.2020.198165.
- [36] Gilchrist JM, Dandapat S. Neuromuscular Mimics of Entrapment Neuropathies of Upper Extremities. *Hand (N Y)*. 2020 Sep;15(5):599-607. doi: 10.1177/1558944719898801.
- [37] Cejas C, Rollán C, Michelin G, Nogués M. High resolution neurography of the brachial plexus by 3 Tesla magnetic resonance imaging. *Radiologia*. 2016 Mar-Apr;58(2):88-100. doi: 10.1016/j.rx.2015.12.002.
- [38] Murthy NK, Fritchie KJ, Amrami KK, Rose PS, Spinner RJ. Diffuse Neuritis Ossificans of the Brachial Plexus: Case Report and Review of the Literature. *World Neurosurg*. 2020 Sep;141:363-366. doi: 10.1016/j.wneu.2020.06.154.
- [39] van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. *Nat Rev Neurol*. 2011 May 10;7(6):315-22. doi: 10.1038/nrneurol.2011.62.
- [40] Martinoli C, Gandolfo N, Perez MM, Klauser A, Palmieri F, Padua L, Tagliafico A. Brachial plexus and nerves about the shoulder. *Semin Musculoskelet Radiol*. 2010 Nov;14(5):523-46. doi: 10.1055/s-0030-1268072.
- [41] Vitturi BK, Grandis M, Beltramini S, Orsi A, Schenone A, Icardi G, Durando P. Parsonage-Turner syndrome following coronavirus disease 2019 immunization with ChAdOx1-S vaccine: a case report and review of the literature. *J Med Case Rep*. 2021 Dec 13;15(1):589. doi: 10.1186/s13256-021-03176-8.
- [42] Lhomme S, Abravanel F, Cintas P, Izopet J. Hepatitis E Virus Infection: Neurological Manifestations and Pathophysiology. *Pathogens*. 2021 Dec 3;10(12):1582. doi: 10.3390/pathogens10121582.
- [43] Krishnan KR, Sneag DB, Feinberg JH, Wolfe SW. Anterior Interosseous Nerve Syndrome Reconsidered: A Critical Analysis Review. *JBS Rev*. 2020 Sep;8(9):e2000011. doi: 10.2106/JBJS.RVW.20.00011.
- [44] Vital JM, Boissière L. Total disc replacement. *Orthop Traumatol Surg Res*. 2014 Feb;100(1 Suppl):S1-14. doi: 10.1016/j.otsr.2013.06.018.
- [45] Ikeda S. [Pathogenesis and treatment of brachial plexus neuritis]. *Rinsho Shinkeigaku*. 2013;53(11):969-73. doi: 10.5692/clinicalneuro.53.969.
- [46] Aymond JK, Goldner JL, Hardaker WT Jr. Neuralgic amyotrophy. *Orthop Rev*. 1989 Dec;18(12):1275-9.
- [47] Sigamoney KV, Rashid A, Ng CY. Management of Atraumatic Posterior Interosseous Nerve Palsy. *J Hand Surg Am*. 2017 Oct;42(10):826-830. doi: 10.1016/j.jhsa.2017.07.026.
- [48] Mclean BN, Gulliver J, Dalton HR. Hepatitis E virus and neurological disorders. *Pract Neurol*. 2017 Aug;17(4):282-288. doi: 10.1136/practneurol-2016-001588.
- [49] Fenichel GM. Neurological complications of immunization. *Ann Neurol*. 1982 Aug;12(2):119-28. doi: 10.1002/ana.410120202.
- [50] Hershman EB. Brachial plexus injuries. *Clin Sports Med*. 1990 Apr;9(2):311-29.
- [51] Chance PF. Molecular basis of hereditary neuropathies. *Phys Med Rehabil Clin N Am*. 2001 May;12(2):277-91.
- [52] Harris JD, Lintner DM. Nerve injuries about the elbow in the athlete. *Sports Med Arthrosc Rev*. 2014 Sep;22(3):e7-15. doi: 10.1097/JSA.0000000000000038.

- [53] Ayoub T, Raman V, Chowdhury M. Brachial neuritis caused by varicella-zoster diagnosed by changes in brachial plexus on MRI. *J Neurol*. 2010 Jan;257(1):1-4. doi: 10.1007/s00415-009-5266-4.
- [54] van Alfen N, Hannibal MC, Chance PF, van Engelen BGM. Hereditary Neuralgic Amyotrophy – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY. 2008 Feb 27 [updated 2012 Dec 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews* [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.
- [55] van Alfen N, van Engelen BG, Hughes RA. Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). *Cochrane Database Syst Rev*. 2009 Jul 8;2009(3):CD006976. doi: 10.1002/14651858.CD006976.pub2.
- [56] Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis E virus: Infection beyond the liver? *J Hepatol*. 2017 May;66(5):1082-1095. doi: 10.1016/j.jhep.2016.11.016.